Full archive
Pharmacogenomics
Week of 8 September 2026
8 articles
Geno'X Veille — genox-veille.fr
Key takeaways this week
- ►HLA-A 32:01 — first marker associated with lamotrigine-induced DRESS in a US population (OR 16.4), absent from commercial pharmacogenomic panels.
- ►CYP3A5 — tacrolimus dosing algorithm integrating donor and recipient genotypes, with clearance reduced by 33% under fluconazole.
- ►CYP2D6 — higher metabolizer status associated with lower mortality on metoprolol (HR 0.82), in 996 patients followed for 101 months.
- ►CYP2C19 — no genotype effect on escitalopram efficacy in post-stroke depression, across 148 treated patients.
- ►Preemptive genotyping — 90% of adults on cardiovascular medication receive at least one drug with an actionable drug-gene interaction, and panel testing multiplies opportunities to reuse a result (83% versus 4% for SLCO1B1).
8 articles of 8
Sort
HLA-A
PubMed★ Top pick
HLA-A*32:01 and Lamotrigine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms
Lamotrigine-induced DRESS
9
New interactionAdverse reaction
JAMA Netw Open 2026· SepRead
Diabetes
PubMedGenetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts
Type 2 diabetes — variability in glucose-lowering drug response
7
DiabetesNew interaction
Diabetes Obes Metab 2026· SepRead
CYP2D6
PubMedCYP2D6 Metabolizer Status and Mortality in Metoprolol Users
Cardiovascular disease — metoprolol therapy
7
New interaction
Clin Transl Sci 2026· SepRead
CYP3A5
PubMedPrecision Dosing of Tacrolimus in Liver Transplantation: Integrating Donor-Recipient CYP3A5 Pharmacogenomics and Drug Interactions
Liver transplantation — tacrolimus immunosuppression
6
CPIC Level ADose recommendation
CPT Pharmacometrics Syst Pharmacol 2026· SepRead
CYP2C19
PubMedClinical outcomes stratified by CYP2C19 phenotypes in intracranial artery stenting patients with genotype-guided antiplatelet regimens: a real-world single-center retrospective cohort study
Intracranial artery stenosis — stenting
6
CardiologyCPIC Level APreemptive genotyping
Pharmacogenet Genomics 2026· AugRead
Diabetes
PubMedDispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross-sectional study
Cardiovascular disease — exposure to actionable pharmacogenetic drugs
6
DiabetesPreemptive genotyping
Clin Pharmacol Ther 2026· SepRead
CYP2C19
PubMedAssociation Between CYP450 Polymorphisms and Treatment Outcomes of Escitalopram and Venlafaxine in Patients with Post Stroke Depression
Post-stroke depression
5
PsychiatryCPIC Level A
Neuropsychiatr Dis Treat 2026· SepRead
SLCO1B1
PubMedGenetic variation in SLCO1B1 is associated with methotrexate intolerance symptoms in juvenile idiopathic arthritis patients
Juvenile idiopathic arthritis — methotrexate intolerance
5
DiabetesNew interactionAdverse reaction
Pharmacogenet Genomics 2026· SepRead
References and sources
- HLA-A — Lamotrigine-induced DRESS. JAMA Netw Open 2026. PMID 42684703. Score 9/10. https://pubmed.ncbi.nlm.nih.gov/42684703/
- CYP3A5 — Liver transplantation — tacrolimus immunosuppression. CPT Pharmacometrics Syst Pharmacol 2026. PMID 42687584. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42687584/
- Type 2 diabetes — variability in glucose-lowering drug response. Diabetes Obes Metab 2026. PMID 42681821. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42681821/
- CYP2D6 — Cardiovascular disease — metoprolol therapy. Clin Transl Sci 2026. PMID 42678095. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42678095/
- CYP2C19 — Post-stroke depression. Neuropsychiatr Dis Treat 2026. PMID 42703526. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42703526/
- CYP2C19 — Intracranial artery stenosis — stenting. Pharmacogenet Genomics 2026. PMID 42687502. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42687502/
- SLCO1B1 — Juvenile idiopathic arthritis — methotrexate intolerance. Pharmacogenet Genomics 2026. PMID 42690100. Score 5/10. https://pubmed.ncbi.nlm.nih.gov/42690100/
- Cardiovascular disease — exposure to actionable pharmacogenetic drugs. Clin Pharmacol Ther 2026. PMID 42677489. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42677489/